Genetic Downregulation of Interleukin‐6 Signaling, Coagulation Function, and Risk of Thromboembolic Disease
Journal of the American Heart Association · 16.12.2025 · 14 (24)
DOI: 10.1161/jaha.125.043972 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 16.12.2025. Verfasst von Iyas Daghlas und 1 weiteren Autor:innen. Beteiligte Einrichtung: UCSF Weill Institute for Neurosciences, Department of Neurology University of California San Francisco San Francisco CA. Hauptthemen laut MEDLINE: Interleukin-6, Blood Coagulation, Venous Thromboembolism, Receptors, Interleukin-6. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Although genetic evidence supports IL‐6 (interleukin‐6) signaling inhibition as protective against atherosclerotic disease, its potential effects on thromboembolic outcomes are not well established. We conducted a Mendelian randomization analysis to investigate the association of genetically proxied IL‐6 signaling inhibition with venous thromboembolism, cardioembolic stroke, and coagulation cascade protein levels.
Methods
IL‐6 signaling inhibition was proxied using the rs2228145 IL6R missense variant, which impairs classical IL‐6 signaling and lowers CRP (C‐reactive protein) levels. Genetic associations with thromboembolic disease outcomes were obtained from genome‐wide association studies of venous thromboembolism (81 190 cases) and cardioembolic stroke (10 804 cases). As atherosclerotic comparator traits, we included coronary artery disease (181 522 cases) and large‐artery atherosclerotic stroke (6399 cases). Genetic associations with 35 coagulation cascade protein levels were obtained from the UK Biobank (n=6218) and deCODE cohorts (n=35 559). Mendelian randomization estimates were derived using the Wald ratio method, scaled per 1‐unit decrease in natural log‐transformed CRP levels.
Results
Genetically proxied IL‐6 signaling inhibition was associated with increased risk of venous thromboembolism (odds ratio [OR], 1.31 [95% CI, 1.16–1.47], P =6.5×10 −6 ) but not with cardioembolic stroke (OR, 1.25 [95% CI, 0.73–2.14], P =0.42). Conversely, protective associations were observed for both coronary artery disease and large‐artery atherosclerotic stroke. Proteomic analyses demonstrated significant reductions in levels of 5 procoagulant and 7 anticoagulant or antifibrinolytic proteins.
Conclusions
These findings suggest that IL‐6 signaling inhibition dysregulates coagulation homeostasis and increases venous thromboembolism risk. Further experimental, translational, and epidemiologic studies are warranted to delineate underlying mechanisms and to evaluate thromboembolic safety in pharmacologic IL‐6 signaling inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCSF Weill Institute for Neurosciences, Department of Neurology University of California San Francisco San Francisco CA.
- Department of Epidemiology and Biostatistics School of Public Health, Imperial College London London United Kingdom.
ORCID-Profile: Iyas Daghlas, Dipender Gill
Zitieren
APA
Daghlas, I., & Gill, D. (2025). Genetic Downregulation of Interleukin‐6 Signaling, Coagulation Function, and Risk of Thromboembolic Disease. Journal of the American Heart Association, 14(24). https://doi.org/10.1161/jaha.125.043972
Vancouver
Daghlas I, Gill D. Genetic Downregulation of Interleukin‐6 Signaling, Coagulation Function, and Risk of Thromboembolic Disease. Journal of the American Heart Association. 2025;14(24). doi:10.1161/jaha.125.043972
BibTeX
@article{Daghlas2025,
author = {Daghlas, Iyas and Gill, Dipender},
title = {Genetic Downregulation of Interleukin‐6 Signaling, Coagulation Function, and Risk of Thromboembolic Disease},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {24},
doi = {10.1161/jaha.125.043972}
}
EUVIMED